An oligosaccharide-based HIV-1 2G12 mimotope vaccine induces carbohydrate-specific antibodies that fail to neutralize HIV-1 virions. - Wikidata - wikimedia - TriplyDB

An oligosaccharide-based HIV-1 2G12 mimotope vaccine induces carbohydrate-specific antibodies that fail to neutralize HIV-1 virions.

An oligosaccharide-based HIV-1 2G12 mimotope vaccine induces carbohydrate-specific antibodies that fail to neutralize HIV-1 virions.

http://www.wikidata.org/entity/Q36924968

about

Recent strategies targeting HIV glycans in vaccine design Designing synthetic vaccines for HIV Glycotherapy: new advances inspire a reemergence of glycans in medicine Antibody 2G12 Recognizes Di-Mannose Equivalently in Domain- and Nondomain-Exchanged Forms but Only Binds the HIV-1 Glycan Shield if Domain Exchanged Vaccine Elicitation of High Mannose-Dependent Neutralizing Antibodies against the V3-Glycan Broadly Neutralizing Epitope in Nonhuman Primates In-solution virus capture assay helps deconstruct heterogeneous antibody recognition of human immunodeficiency virus type 1 Effects of neighboring glycans on antibody-carbohydrate interaction.Defining criteria for oligomannose immunogens for HIV using icosahedral virus capsid scaffolds.Synthetic carbohydrate antigens for HIV vaccine design.Rational antibody-based HIV-1 vaccine design: current approaches and future directions Multivalent glycocluster design through directed evolution.Very few substitutions in a germ line antibody are required to initiate significant domain exchange.Small molecule mimetics of an HIV-1 gp41 fusion intermediate as vaccine leads.Prime-boost immunization of rabbits with HIV-1 gp120 elicits potent neutralization activity against a primary viral isolate.Crystal structure of the HIV neutralizing antibody 2G12 in complex with a bacterial oligosaccharide analog of mammalian oligomannose Directed evolution of multivalent glycopeptides tightly recognized by HIV antibody 2G12.Multivalent glycoconjugates as anti-pathogenic agents Perorally active nanomicellar formulation of quercetin in the treatment of lung cancer Screening and identification of mimotopes of the major shrimp allergen tropomyosin using one-bead-one-compound peptide libraries High-mannose glycan-dependent epitopes are frequently targeted in broad neutralizing antibody responses during human immunodeficiency virus type 1 infection.Antibodies elicited by yeast glycoproteins recognize HIV-1 virions and potently neutralize virions with high mannose N-glycans.Neutralizing antibodies to HIV-1 induced by immunization.Modular synthesis of N-glycans and arrays for the hetero-ligand binding analysis of HIV antibodies A new model for the presentation of tumor-associated antigens and the quest for an anticancer vaccine: a solution to the synthesis challenge via ring-closing metathesis.Carbohydrate vaccines: developing sweet solutions to sticky situations?Glycan array: a powerful tool for glycomics studies.Potential of carbohydrate-binding agents as therapeutics against enveloped viruses.Carbohydrate targets in HIV vaccine research: lessons from failures.Carbohydrate chemistry in drug discovery.Toward automated oligosaccharide synthesis.Recent advances in developing synthetic carbohydrate-based vaccines for cancer immunotherapies.Synthesis of high-mannose 1-thio glycans and their conjugation to protein.A solution NMR study of the interactions of oligomannosides and the anti-HIV-1 2G12 antibody reveals distinct binding modes for branched ligands.Recent progress in the field of neoglycoconjugate chemistry.Recent Developments in Synthetic Carbohydrate-Based Diagnostics, Vaccines, and Therapeutics.HIV-1 envelope glycoprotein immunogens to induce broadly neutralizing antibodies.Broadly Neutralizing Antibody-Guided Carbohydrate-Based HIV Vaccine Design: Challenges and Opportunities.High temperature SELMA: evolution of DNA-supported oligomannose clusters which are tightly recognized by HIV bnAb 2G12.Cyclopeptide scaffolds in carbohydrate-based synthetic vaccines.Synthetically defined glycoprotein vaccines: current status and future directions.

P2860

Q26823603-92939972-582A-40A2-B7C5-617DCF0465BE Q26862617-54F9C53E-99F6-42EA-AE93-ED3A0BBFCFBA Q27027997-4C5BDAD0-C3E7-47AA-9149-BD354FE5CE1E Q27664038-B953AA57-60A1-47C5-8123-569918A8A4F9 Q33612459-5CCF977E-E961-48AC-ABF9-9F50830BF2FC Q33725718-69199DC9-3DAE-42D1-9166-8C2D99A37641 Q33817230-5D78FC02-9387-4016-BD13-2C2616570519 Q33840789-1891ABF1-7D72-4359-B360-4179C9D1519F Q33909079-9163F73D-54E7-480A-8F14-A618ED471CA4 Q33937285-E5BB16AA-55E2-4A9B-8BA7-98E254510CFD Q34108462-6727A8EE-E412-426F-808C-2F14ED91D7FF Q34178341-40669CA7-2078-415F-9BD4-1876A7183BA1 Q34412591-1324646B-ACD7-4ED0-8CC9-E6CC3D3AC17A Q34551010-E72B1676-8AB9-48E7-87EE-12C81FDA5307 Q35119778-6A2491B8-D3FA-4B87-8550-C5EEEB9506B5 Q35124652-0F587FFE-2C39-48A1-96E1-21021ED9B261 Q35444698-D699D72E-57AF-4D3A-AA47-884F20B045CE Q35753059-20A5039C-B98C-43DA-B505-167B51DD4D65 Q35771900-B0CB3A30-1410-4721-B1A9-FEBBD256D159 Q35826509-9C3DEFFE-0658-4931-8A19-973AE2D5F846 Q36079874-46088B08-900D-4F67-8393-DC7908D9B6C4 Q36603515-0D3A3A48-EC8D-486E-B7B6-003787EEAFEC Q36725490-D81D1A8E-264B-4E21-B352-7A16C3535478 Q37380026-FC71F603-E392-49AE-9437-016522C493F5 Q37426039-05AB97C2-5FD7-4E34-A8AC-6626D09895A7 Q37636120-C9081577-5B70-425F-B7AB-BC8BDAF89DFD Q37767654-32E2BB31-88A4-4D72-9FE6-FFB632B61550 Q37773298-E10C4603-0703-4945-BE9C-5E33B9AE4AC0 Q37853437-1B5F022A-26DE-4A7A-B686-0CFD54931AA4 Q37962848-B2129451-46A9-4259-BB57-EA671C7D4A8D Q37993590-87D27F6B-CF1F-4D7A-A1AE-A96FF7CC2ABA Q38308862-2174C71B-60F5-4F5E-AFBF-8E9A4A1B8A45 Q38337811-26923BAA-A29D-48DC-9957-B8DED1175D4C Q38472393-C4B6CBCC-E832-4764-9F5D-B8209D080B21 Q38533442-605F2AD3-A30F-4B7D-A8E9-07AE87DDCD72 Q38665463-3D7F619C-950E-41C6-85A5-EEC3E57BFF5D Q38695294-5491141F-1367-4567-BCD0-8915391C568D Q38732360-7EF0A88E-4722-4308-8BC0-C8CB7EA35ABC Q39169715-1224576B-9F2E-4AA7-BF01-AC86AE8521E3 Q39375701-EA78AAE8-CB04-4C39-9310-87D926190DB1

P2860

An oligosaccharide-based HIV-1 2G12 mimotope vaccine induces carbohydrate-specific antibodies that fail to neutralize HIV-1 virions.

http://www.wikidata.org/entity/Q36924968

description

2008 nî lūn-bûn

@nan

2008年の論文

@ja

2008年論文

@yue

2008年論文

@zh-hant

2008年論文

@zh-hk

2008年論文

@zh-mo

2008年論文

@zh-tw

2008年论文

@wuu

2008年论文

@zh

2008年论文

@zh-cn

name

An oligosaccharide-based HIV-1 ...... l to neutralize HIV-1 virions.

@en

type

label

An oligosaccharide-based HIV-1 ...... l to neutralize HIV-1 virions.

@en

prefLabel

An oligosaccharide-based HIV-1 ...... l to neutralize HIV-1 virions.

@en

P1433

Q36924968-802FFC3B-0770-4699-86E9-A7C818DE6B76

P1476

Q36924968-CA33568E-4BE6-4C1A-8F89-780D9900B24E

P2093

Q36924968-28A96A81-5FE0-42DA-B94E-CFAD6D5108DE

Q36924968-885564FC-B60C-470E-B663-AB3BD3CE93C5

Q36924968-AF1320A6-7590-4131-ACF2-720DB2EA714E

Q36924968-B1ED397F-4156-4A43-B931-69EE77FEDC5B

Q36924968-B8D9D72A-3600-4E43-A549-D46CDDA907D8

Q36924968-BABEC338-A982-4FC8-A3E1-FE2549E91F3B

Q36924968-C08B4723-9C5C-47F2-B1FB-2E88954DCA97

Q36924968-C096A7BC-8D9B-4E67-A06E-4B28A094C592

Q36924968-E3D9EC5F-4DAB-4CC6-93B2-09653004E7B5

Q36924968-E532A898-23FA-4E14-A372-9A8132CF8879

P2860

Q36924968-0A9E71B3-86E8-4B57-ADF7-2C0769BA22AB

Q36924968-0DB3F33F-343A-46F6-AD8B-2543A36913B5

Q36924968-1187AA37-9579-489A-A08C-1E735DCA7E2D

Q36924968-2F5E75F6-3EDF-478F-B74A-583B5D17D88F

Q36924968-3BACAA7A-92BC-41CC-BC56-94E31A9FBCB8

Q36924968-40AC7CF3-500A-48F4-A396-7DA2B752E856

Q36924968-529A2D24-9AD4-4479-847E-ED938F240D10

Q36924968-5306C771-660F-441C-B5BE-3C58F2CE0513

Q36924968-5470E1D2-7C58-4C92-AFE5-ED646188C9D5

Q36924968-5BD4910A-BC1C-4418-BCDC-00DC01E6C75C

P304

Q36924968-B3087F3E-CE24-4824-91BE-7B93F33994FC

P31

Q36924968-8DB31DDC-17AE-4A45-BB34-8A4BD9AE86FC

P356

Q36924968-D1DFD84B-4A84-44B0-A088-51E5ADF8E12C

P407

Q36924968-B62A0216-1BAC-4B65-B060-D715631F756E

P433

Q36924968-784572B8-DD0A-474A-9144-07C0D708CD60

P478

Q36924968-F354BB82-9BAF-4732-AE12-E020BFFE6844

P577

Q36924968-5F3F7393-5432-4791-9987-419F503ED143

P5875

Q36924968-7374191F-429C-42D1-B140-ADCEA03B6C94

P698

Q36924968-6A525157-748C-41DC-9E1D-C1551A3F919C

P921

Q36924968-057E4C07-8BE0-47F4-A3B4-FEA0CC76D2CB

Q36924968-CD5A6386-7BC5-4797-8FE3-F295767C9C2D

P932

Q36924968-9622A520-0026-4B63-9CD5-222C85F178C9

P356

PNAS.0807837105

P1433

Proceedings of the National Academy of Sciences of the United States of America

P1476

An oligosaccharide-based HIV-1 ...... l to neutralize HIV-1 virions.

@en

P2093

David W Opalka

http://www.w3.org/2001/XMLSchema#string

Deborah D Nahas

http://www.w3.org/2001/XMLSchema#string

Hong C Song

http://www.w3.org/2001/XMLSchema#string

Isaac J Krauss

http://www.w3.org/2001/XMLSchema#string

John W Shiver

http://www.w3.org/2001/XMLSchema#string

Joseph G Joyce

http://www.w3.org/2001/XMLSchema#string

Karen M Grimm

http://www.w3.org/2001/XMLSchema#string

Mark T Esser

http://www.w3.org/2001/XMLSchema#string

Meizhen Feng

http://www.w3.org/2001/XMLSchema#string

Michael Chastain

http://www.w3.org/2001/XMLSchema#string

P2860

Antibody domain exchange is an immunological solution to carbohydrate cluster recognition

Crystal structure of the broadly cross-reactive HIV-1-neutralizing Fab X5 and fine mapping of its epitope

Broadly neutralizing anti-HIV antibody 4E10 recognizes a helical conformation of a highly conserved fusion-associated motif in gp41

The antigenic structure of the HIV gp120 envelope glycoprotein

Human monoclonal antibody 2G12 defines a distinctive neutralization epitope on the gp120 glycoprotein of human immunodeficiency virus type 1

Immunogenicity and protective efficacy of Bacillus anthracis poly-gamma-D-glutamic acid capsule covalently coupled to a protein carrier using a novel triazine-based conjugation strategy.

Targeting the carbohydrates on HIV-1: Interaction of oligomannose dendrons with human monoclonal antibody 2G12 and DC-SIGN

Dissection of the carbohydrate specificity of the broadly neutralizing anti-HIV-1 antibody 2G12.

The broadly neutralizing anti-human immunodeficiency virus type 1 antibody 2G12 recognizes a cluster of alpha1-->2 mannose residues on the outer face of gp120.

Structure and mechanistic analysis of the anti-human immunodeficiency virus type 1 antibody 2F5 in complex with its gp41 epitope.

P304

15684-15689

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1073/PNAS.0807837105

http://www.w3.org/2001/XMLSchema#string

P407

P433

41

http://www.w3.org/2001/XMLSchema#string

P478

105

http://www.w3.org/2001/XMLSchema#string

P577

2008-10-06T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

23303144

http://www.w3.org/2001/XMLSchema#string

P698

18838688

http://www.w3.org/2001/XMLSchema#string

P921

oligosaccharide

P932

2562416

http://www.w3.org/2001/XMLSchema#string